Found 97 articles
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
Cingulate Inc. today announced the initiation of the first Phase 3 clinical trial of its lead candidate CTx-1301, a novel, investigational, trimodal, extended release tablet formulation of dexmethylphenidate, a compound approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD).
Cingulate Inc. announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on Friday December 16, 2022, at 9:20 a.m. CST.
Cingulate Inc. Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update.
Cingulate Inc. announced it has executed a Master Services Agreement with Societal CDMO, Inc., a bi-coastal contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.
Cingulate Inc. (NASDAQ: CING) today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be collaborating with NOCD, an organization that facilitates access to online therapy for people with obsessive-compulsive disorder (OCD) through its innovative telehealth platform.
Cingulate Inc. announced findings from its formulation study for CTx-2103, the Company’s asset for the management of anxiety-related disorders.
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
Cingulate Inc. announced its financial results for the quarter ended June 30, 2022, and provided a clinical and business update.
Anavex Life Sciences Corp. announced the first entire clinical gene pathway data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia study at the Alzheimer’s Association International Conference, taking place in San Diego, CA and virtually on July 31 – August 4, 2022.
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year
Cingulate Inc. announced that Chief Financial Officer, Lou Van Horn, has been named a 2022 CFO of the Year by the Kansas City Business Journal.
MindMed, Scripps Research, Cingulate Therapeutics and the University of Pennsylvania discuss innovative treatments on the horizon for the treatment of anxiety disorder.
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders
Cingulate Inc. today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders.
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, will present a company overview at the Diamond Equity Research 2022 Virtual Emerging Growth Invitational on Thursday, June 23, 2022.
Cingulate Inc. announced that Chairman and CEO Shane J. Schaffer, PharmD, and preeminent board-certified psychiatrist and Cingulate scientific advisor Dr. Ann Childress, MD, will participate in a live Benzinga All Access event on June 3, 2022, at 8:45 a.m. CST.
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders
Cingulate Inc. announced the Company has completed enrollment in its study to determine the appropriate formulation of its third asset, CTx-2103, for the management of anxiety-related disorders.
Cingulate Inc. announced that Chairman and Chief Executive Officer, Shane J. Schaffer, and Chief Medical Officer, Matthew Brams, M.D., will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, from 3:00-3:30 p.m. ET, at the Fontainebleau Miami Beach Hotel, Miami, FL.
Cingulate Inc. announced its financial results for the three months ended March 31, 2022, and provided a clinical and business update, which includes the announcement of first subject dosing in its human formulation study of CTx-2103 for the treatment of anxiety.
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today the publication of REL-1017 preclinical data in the peer-reviewed journal, Frontiers in Pharmacology.
Cingulate Inc. announced that its Chairman and Chief Executive Officer, Shane J. Schaffer, recently presented a company overview at NobleCon18 - Noble Capital Markets’ Eighteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida.